Article Text

Download PDFPDF
Reversible blindness with macrophage activation syndrome: an unusual presentation of secondary antiphospholipid syndrome
  1. Debroop Sengupta,
  2. Kamal Poddar,
  3. Upamanyu Bag and
  4. Sandip Ghosh
  1. General Medicine, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
  1. Correspondence to Dr Debroop Sengupta; debroop_sengupta{at}


Blindness due to retinal vascular thrombosis is a dreadful complication of antiphospholipid syndrome (APS). The latter may be present in isolation (ie, primary) or may occur secondary to other connective tissue diseases like lupus. Here we present an adolescent girl with bilateral painless loss of vision as a result of central retinal vessel thrombosis due to secondary APS. Her condition was further complicated by the presence of autoimmune haemolytic anaemia and the development of macrophage activation syndrome while being evaluated for her blindness. Prompt treatment with glucocorticoids and anticoagulants could halt the devastating disease process.

  • Retina
  • Systemic lupus erythematosus
  • Immunology
  • Haematology (incl blood transfusion)

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors DS collected patient data and materials, wrote the original draft, and was responsible for literature search, review and editing. KP collected patient data and materials. UB collected patient data and materials. SG collected patient data and materials, and was responsible for review and editing.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.